PCM
VERV

Pinz Capital Management’s Verve Therapeutics VERV Stock Holding History

Pinz Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-51,800
Closed -$792K – 167
2022
Q2 		$792K Buy
+51,800
New +$802K 0.54% 55
2021
Q3 		– Sell
-34,800
Closed -$2.1M – 388
2021
Q2 		$2.1M Buy
+34,800
New +$1.44M 0.63% 56

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pinz Capital Management's VERV Position: Q3 2022 in Review

Pinz Capital Management sold out of Verve Therapeutics (VERV) in Q3 2022, closing a stake of 51,800 shares — an estimated $792K sold.

Pinz Capital Management first reported a position in VERV in Q2 2021 and held it in 2 quarters. The position peaked at $2.1M in Q2 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q3 2022.

  • Pinz Capital Management reported no remaining Verve Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Pinz Capital Management sold 51,800 Verve Therapeutics shares in Q3 2022, an estimated $792K.
  • Pinz Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 2 quarters.
  • Pinz Capital Management's Verve Therapeutics position peaked at $2.1M in Q2 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.